Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation allocations rather than operational financial performance.
Material Changes
On December 31, 2012, Non-Executive Directors were allocated notional Ordinary Shares at a price of £13.43 per share and notional American Depositary Shares (ADSs) at a price of $43.39 per ADS. These allocations covered the service period from October 1, 2012, to December 31, 2012. The Company and Directors were informed of these allocations on January 2, 2013.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share interests in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Share Allocation Price: Notional Ordinary Shares were allocated at £13.43 per share.
- ADS Allocation Price: Notional ADSs were allocated at $43.39 per ADS.
- Service Period: Allocations relate to the period of service from October 1, 2012, to December 31, 2012.
- Notification Date: The Company and Directors were notified of these allocations on January 2, 2013.
- Scope: This filing details changes in interests for Non-Executive Directors only and does not contain consolidated financial results.